Aardvark Therapeutics Faces Class Action Over Misleading Safety Claims
Aardvark Therapeutics Faces Class Action Over Misleading Safety Claims
Aardvark Therapeutics, Inc. (NASDAQ: AARD), has recently found itself embroiled in a complex securities class action. This lawsuit revolves around allegations that the company overstated the safety profile of its drug ARD-101. The implications of this case are profound, particularly for shareholders who invested during a turbulent period marked by steep declines in stock values.
The decline began when Aardvark announced a voluntary pause in its Phase 3 HERO trial due to concerning cardiac observations linked to higher than targeted therapeutic doses. This announcement marked a pivotal moment; it triggered a swift downgrade from Morgan Stanley Research, which slashed its price target from $29 to a mere $7—a staggering drop of about 75.9%. On the same day, Aardvark’s stock closed at $5.47, reflecting a significant decline of 56.2% from the day prior, having lost $7.02 in value per share. This was followed by further downgrades from other financial analysts, leading to rising concerns among investors.
The class action aims to recover losses for shareholders who acquired AARD shares between February 13, 2025, and May 14, 2026. According to Joseph E. Levi, the attorney overseeing the case, the misleading representations by Aardvark about the drug's safety have caused significant investor harm, as expectations built on these claims led to the eventual crash in share prices.
Timeline of Analyst Downgrades
- - February 27, 2026: Aardvark discloses the voluntary pause in the Phase 3 HERO trial, withdrawing expectations for topline data in Q3 2026.
- - March 2, 2026: Morgan Stanley downgrades AARD to Equal-weight and reduces its price target from $29 to $7 (down approximately 75.9%).
- - March 2, 2026: BTIG lowers its price target from $26 to $9 (approximately 65.4%), citing increasing risks with the HERO trial.
- - March 2, 2026: Bank of America trims its target from $25 to $21 (approximately 16%).
- - May 14, 2026: The FDA places a full clinical hold on the ARD-101 IND, affecting the HERO trial and its open-label extension.
These alterations led to heightened anxiety among investors, especially as shares fell to an alarming $4.57 on May 15, representing a 32.1% decline or a loss of $2.16 per share following the FDA's announcement. Investors who bought shares during this turbulent time at inflated prices may qualify to participate in the class action.
Why This Lawsuit Matters for Investors
The ramifications of such class actions extend beyond mere financial restitution. They serve as a critical reminder of the need for transparency in corporate communications. When analysts craft their expectations based on information that proves to be misleading, it can lead to catastrophic financial consequences for innocent investors. The steep drop from $29 to $7 within days of the trial pause illustrates this potential for catastrophic investor harm.
Those interested in participating should gather brokerage records to confirm their purchase dates and share amounts. The deadline to apply for lead plaintiff appointment is set for October 13, 2026. Lead plaintiffs play a vital role in representing the entire class, particularly those with extensive documented losses.
Even investors who sold their shares prior to the lawsuit announcement may still be eligible for recovery since eligibility is determined by purchase date rather than current holding status.
Conclusion
The situation surrounding Aardvark Therapeutics presents a cautionary tale about the importance of integrity in corporate representations and stakeholder communications. For investors, this class action presents a dedicated effort to seek accountability and make whole those affected by the misleading claims surrounding ARD-101. Potential participants are encouraged to act swiftly to ensure they do not miss out on their chance for restitution.
For more information, investors can reach out to Joseph E. Levi, Esq. at email or call (888) SueWallSt for guidance on their participation in this pressing legal matter.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.